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1. Introduction
Infective endocarditis (IE) is a life threatening disease caused by a bacterial infection of the
endocardial surfaces of the heart. It is typified by the formation of septic thrombi or vegetative
growth on the heart valve. Typically, both platelets and fibrin are deposited on exposed
extracellular matrix proteins as part of the normal response to damage of the endocardium [1].
However, this sterile platelet-fibrin nidus facilitates colonisation of the endocardium by bacteria
in the bloodstream [2]. Following attachment, bacteria can recruit platelets from the circula‐
tion inducing platelet activation and platelet aggregation. This results in the development of
large macroscopic vegetations which resist infiltration by both immune cells and antibiotics
making IE a difficult disease to treat. These vegetations commonly occur on the heart valves and
can disrupt hemodynamic patterns within the heart. This puts undue force on often already
compromised valves, leading to congestive heart failure [3]. IE is notoriously difficult to treat,
requiring aggressive multi-antibiotic therapy often coupled with surgery to remove vegeta‐
tions and/or replace the infected valve [4]. Therapy is successful when all traces of bacteria are
absent from the blood stream. Multiple species of bacteria have been isolated from the infect‐
ed vegetations of patients [5, 6] with IE but the streptococci are amongst the most common cause,
second only to the staphylococci  whose interactions with human platelets  are discussed
elsewhere in this book (Chapter X). Indeed, in a recent prospective study, the role of streptococ‐
ci in IE is masked by the growing incidence of staphylococcal IE resulting from the increased use
of medical procedures leaving streptococci as a main cause of IE in the normal population [7, 8].
2. The Streptococcus
The streptococci are a large family of gram positive coccus shaped bacteria that reside in the
mouth, intestine, upper respiratory tract and the skin. Most have a commensal relationship
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with their host. However, as opportunistic pathogens they can cause disease if they gain access
to normally sterile sites of the body such as the bloodstream. Most streptococci isolated from
patients with IE are of oral origin [9], normally found colonising the salivary tooth pellicle
through the interactions of surface expressed virulence factors, called adhesins, with specific
moieties or motifs on host proteins or cells. When these streptococci enter the bloodstream
these bacterial components participate in additional interactions with platelets. Whether this
is by design or simply as a consequence of conserved motifs within the human host is unknown
but regardless their interaction with human platelets is a key step in the pathogenesis of IE.
3. Platelet biology I: Haemostatic function
In the absence of infection, platelets act as sentinels of vascular integrity, patrolling the
endothelium for sites of damage. Upon vascular damage these small anucleate cells interact
with exposed extracellular matrix proteins via specific receptors expressed on their surface
and a complex yet coordinated series of interactions and signalling events proceed, culminat‐
ing in the formation of a haemostatic plug. Platelet receptor complex GPIb-IX-V recognises
von Willebrand Factor (vWF) bound to exposed collagen fibrils in the subendothelial matrix,
tethering the platelet to the site of damage [10, 11]. This initial interaction is relatively weak
and has a fast on-off rate [12] so the platelet characteristically rolls along the endothelium
breaking and remaking the vWF-GPIb-IV-X interaction [1]. This ‘rolling’ mechanism slows the
platelet sufficiently for additional receptor-ligand contacts and triggers an intracellular signal
resulting in integrin activation and firm adhesion. Firm adhesion is mediated by a combination
of ligand receptor engagements: integrin α2β1 - collagen [13-15]; glycoprotein GPVI - collagen
[16]; α5β1-fibronectin [17]; and αIIbβ3 with fibrinogen and vWF [12, 18]. Once firmly adhered,
the platelet undergoes dramatic rearrangement of its cytoskeleton causing platelet shape
change from its resting discoid form to a dendritic form and finally, to a fully spread platelet
with characteristic filipodia and llamelipodia [19]. During this process, the platelet secretes
signalling molecules, proteins and platelet agonists (ADP, ATP and serotonin) from its
cytoplasmic granules (α- and dense- granules) and synthesizes and secretes thromboxane,
amplifying the platelet response, recruiting and activating nearby platelets. Activated platelets
can undergo platelet aggregation, cross linking with one another via their αIIbβ3 receptors
and the divalent plasma protein fibrinogen. This activation and recruitment of platelets to the
site of injury, in addition to stimulation of the coagulation system and formation of a fibrin
network, forms the haemostatic plug.
4. Platelet biology II: Immune function
The platelet role in haemostasis and thrombosis is well characterised but, at the same time,
their activities can be viewed from an immunological perspective [20]. Their primary role of
maintaining vascular integrity is an essential process in preventing entry of foreign particles
into the blood stream. The epithelial barrier performs a similar function. More specifically,
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however, they produce antimicrobial peptides [21]; possess pathogen recognition receptors
(TLRs)[22, 23]; secrete immunomodulatory molecules [24]; and have specific receptors for
chemokines [25], antibody complexes [26] and complement factors [27]. Critically, as outlined
in this chapter, they interact with and respond to bacteria, all hallmarks of true immune cells.
It is this response, or activation, that is important in the context of IE and provides the basis
for the formation of platelet-bacterial vegetations which characterise this disease.
5. Platelet-bacterial interactions: General observations
Platelet interactions are examined under the broad headings of platelet adhesion, activation
and aggregation. Platelet aggregometry is a useful tool in assessing platelet activation. In
contrast to conventional stimuli such as ADP and thrombin, there is a significant lag time to
the onset of platelet aggregation in response to bacteria [28].The length of this lag is de‐
fined by the sum of platelet-bacterial interactions occurring and can vary between donors,
most likely due to variation in the levels of platelet receptors expressed on the surface and
the concentration of plasma proteins. Platelet-bacterial interactions can be categorized into
direct, indirect or mediated by a secreted bacterial product [29]. A direct interaction occurs
when a bacterial  adhesin binds directly to a platelet  receptor or other surface expressed
component [30].  Bacteria can participate in indirect  interactions with platelets  through a
bridging protein which binds to the bacterium and then to its cognate platelet receptor [31].
When bacteria enter the bloodstream they can bind plasma proteins through specific plasma
binding proteins or they can simply be recognised by soluble elements of the immune system
such  as  immunoglobulins  and  complement  proteins.  Finally,  and  less  common  for  the
streptococcal bacteria, a secreted bacterial product may bind to the platelet causing activa‐
tion  independently  of  bacterial  attachment.  The  ability  of  bacteria  to  propagate  platelet
activation and aggregation facilitates growth of the vegetation and effectively encapsulates
the  bacteria,  hiding  them  from  conventional  immune  cells  and  bacterial  killing  mecha‐
nisms. This chapter will focus on the specific molecular events that lead to initiation of IE,
namely recognition of the platelet by the bacteria (and vice versa) and the ensuing intracellu‐
lar  signalling events  that  lead to  platelet  activation and amplification of  the  platelet  re‐
sponse. As will be evident from the discussion to follow, platelet bacterial interactions are
heterogeneous  in  nature  and  additionally  they  are  multifactorial,  with  most  bacteria
interacting with platelets through more than one mechanism.
6. Streptococcus — Platelet interactions
6.1. Early findings
Streptococcus sanguinis (formally Streptococcus sanguis) is the most common Streptococcus
isolated from the valves of patients with IE [9]. Early studies identified a 115 kDa cell membrane
protein that induced platelet aggregation in platelet rich plasma [32]. This rhamnose rich,
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platelet-aggregation associated protein (PAAP) is glycosylated and was amongst the first
identified bacterial glycoproteins [33]. Bacterial glycoproteins are now thought to be almost
ubiquitous, performing critical roles in host adhesion, resistance to complement killing,
maintenance of cell shape and enzymatic activities that release nutrients from complex
carbohydrates [34]. The platelet receptor for this protein has not been confirmed, however, an
early study showed that S. sanguinis did not induce platelet aggregation in a patient who failed
to respond to collagen suggesting the role of a collagen receptor, possibly α2β1 [35]. Addition‐
ally, Gong et al. isolated platelet membrane proteins of molecular weights 175 kDa, 150 kDa
and 230 kDa that interacted with S. sanguinis 133-79 [36]. The platelet binding domain of PAAP
has been isolated to a 23 kDa fragment [37]. Furthermore, the peptide sequence PGEQGPK
within this fragment conforms to the platelet interactive domain of collagen types I and III,
KPGEPGPK, and antibodies directed against this peptide delayed the onset of aggregation
induced by S. sanguinis [38, 39]. More recently, in an effort to identify the PAAP gene, a putative
collagen binding protein was identified containing two PAAP-like sequences and platelet
aggregation in platelet rich plasma was significantly reduced in response to a mutant lacking
this protein while no changes in platelet adhesion were observed [40]. In conjunction with the
study of Gong et al., this confirmed that S. sanguinis had at least one other adhesin for human
platelets.
6.2. Serine rich repeat glycoproteins
The serine rich repeat (SRR) proteins are a large family of glycosylated bacterial adhesins. SRR
proteins of S. sanguinis and its close relative S. gordonii mediate direct binding of these bacteria
to platelets through sialic acid residues on the GPIbα subunit of the GPIb-V-IX complex [41-43].
Fimbriae-associated protein 1 (Fap1) of S. parasanguinis FW213 was the first SRR protein to be
identified and, while it is reported not to interact with human platelets, studies of Fap1 have
provided important information on the structure of SRR proteins and the nature of their ligand
interactions. SRR proteins share a common domain structure: an N-terminal signal sequence;
a short serine rich repeat region (SR1); a non-repetitive ligand binding region (BR); a larger
serine rich repeat domain (SR2); and a cell wall anchor domain (CW) [41-47]. Like PAAP, SRR
proteins are highly glycosylated. The serine rich repeat domains are decorated with O-linked
carbohydrate residues [48] and the larger SR2 domain is thought to form a stalk like structure,
extending the adhesive N-terminal region from the cell surface. Fap1 is critical for S. parasan‐
guinis adhesion to saliva coated hydroxyapatite (sHA) and biofilm formation [49, 50]. How‐
ever, Fap1 mediated adhesion to sHA is independent of these glycosylations as shown by
mutation of upstream glycosyltransferases critical for glycosylation of the native protein and
subsequent biofilm formation [51].
In contrast to the conserved structural organisation of SRR proteins, the peptide sequence of
the non repetitive region varies significantly and is suggested to explain the differing affinity
of SRR proteins to platelets and other cell types. To date only the SRR proteins of S. sangui‐
nis (SrpA) and S. gordonii (GspB and Hsa) have been demonstrated to interact directly with
human platelets while others, PsrP of S. pneumoniae and Srr-1 of S. agalactiae bind to keratin 10
and 4 in lung epithelial and endothelial cells respectively [52, 53]. The platelet interactive
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domains and specifically the sialic acid binding domain of GspB and Hsa are isolated to the
non repetitive region [43]. Most recently, x-ray crystallography studies of the non-repetitive
ligand binding region of GspB have revealed a modular organization: helical domain; a
domain similar to the binding domain of Staphylococcus aureus collagen binding protein CnaA;
a Siglec domain; and a Unique domain [54]. Interestingly, the Siglec domain, a mammalian
carbohydrate binding domain, was found in Hsa and SrpA but not in the protein sequences
of five other characterised SRR proteins suggesting that this domain is critical for interactions
with GPIbα [54]. Indeed, a point mutation (R484E) in the Siglec domain showed a marked
reduction in binding to glycocalicin, the ectodomain of GPIbα and reduced bacterial load in
the vegetations of a catheterized rat model of infective endocarditis [54].
GPIbα is a glycosylated, type one transmembrane receptor. A long highly glycosylated region
called the macroglobulin region, or mucin-like core, extends from the cell surface presenting
ligand binding domains to the extracellular milieu [55]. The macroglobulin region is decorated
in predominantly O-linked but some N-linked carbohydrates terminating in sialic acid[55].
This highly glycosylated protein backbone is followed by a sulphated tyrosine region, a leucine
rich repeat domain and an N-terminal domain decorated with N-linked sialic acid oligosac‐
charides [55]. Hsa is proposed to bind to both the N-terminal domain and the macroglobulin
region while GspB interactions are isolated to the macroglobulin stalk [43]. Further complexity
is added as GspB and Hsa display distinct preferences for O-linked and N-linked glycosyla‐
tions respectively [43]. The subtle differences in binding affinity of SrpA to sialic acid moieties
remain to be elucidated but studies using anti-GPIbα site specific antibodies isolated the S.
sanguinis interactive region of GPIbα to the N-terminal region and the sulphated tyrosine
region [30]. This suggests that SrpA interacts with human platelets in a distinct mechanism to
GspB and Hsa. However, the ability to bind sialic acid residues is critical as sialidase treated
platelets and glycocalicin support significantly less bacterial binding than the untreated
samples [41-43]. In platelet function studies, deletion of either Hsa or SrpA failed to prevent
platelet aggregation suggesting other platelet-bacterial interactions are needed to induce
platelet activation [41, 56]. In contrast, using an in vitro model of blood flow, platelets were
observed rolling before stably adhering to S. sanguinis 133-79 [41]. This is characteristic of
GPIbα interactions with vWF under shear conditions. When platelets were perfused over an
immobilised strain of S. sanguinis defective in expression of SrpA or an S. gordonii strain
defective in Hsa expression, no rolling or attachment was observed suggesting that these SRR
are essential for initial platelet attachment in the blood stream [41, 56].
7. Antigen I/II family of bacterial adhesins
The antigen I/II family of proteins are ubiquitous to streptococci being found in most published
genomes to date with roles in the development of microbial communities and adhesion to host
cells and proteins [57]. Like the SRR proteins they share a common domain organisation: a
signal sequence; an N-terminal region; an alanine rich repeat domain; a variable domain; a
proline rich repeat region; a C-terminal region and a cell wall anchor domain [58].
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Investigation of the role of the antigen I/II family of adhesins in S. gordonii-platelet interactions
was prompted by the observation that, while adhesion to S. gordonii DL1 was reduced by
mutation of Hsa, the platelet aggregation response remained, suggesting a second interaction
[56]. Indeed, a proteomic approach using cell wall extracts from an aggregating S. gordonii
strain (DL1) and a non aggregating strain (Blackburn) revealed two antigen I/II proteins of
molecular weights 172 kDa and 164 kDa [56]. These were designated SspA and SspB [56].
Mutation of these proteins did not affect platelet adhesion to wildtype S. gordonii or, indeed,
a Hsa mutant. However, platelet aggregation was completely abolished when Hsa, SspA and
SspB were mutated simultaneously [56, 59]. SspA and SspB participate in fluid phase interac‐
tions with salivary glycoprotein gp340, facilitating bacterial clumping which most likely aids
in the development of biofilms [59, 60]. Additionally, they mediate adherence and internali‐
sation into epithelial cells via β1 intregins [57], can bind to collagen type 1 [61] and interact
with other oral microorganisms: Candida albicans [62]; Porphyromonas gingivalis [63]; and
Actinomyces naeslundii [60]. Given their critical role in induction of platelet aggregation it is
tempting to speculate that S. gordonii strains lacking antigen I/II proteins may have reduced
virulence in IE due to failure to propagate platelet activation. However, this remains to be
confirmed in animal models of IE.
The cariogenic and IE causing bacterium S. mutans also produces an antigen I/II adhesin called
PAc, P1 or SpaA that has been shown to be involved in platelet aggregation [64]. PAc is a
LPXTG cell wall associated protein with significant sequence identity to S. gordonii SspA [65].
PAc, like SspA and SspB, has roles in adherence to the salivary pellicle, biofilm formation [66],
collagen dependent invasion of dentinal tubules binding [67]. Clinical strains lacking expres‐
sion of PAc failed to induce aggregation in PRP [64]. Additionally, increasing amounts of anti-
PAc serum dose dependently decreased the rate of platelet aggregation but did not abolish it
[66]. A recent crystallography study examined the detailed structure of the C-terminal in the
context of adherence to the salivary pellicle, specifically the binding of carbohydrate moieties
[68], however, little is known about the putative platelet interactive domain of PAc. Notably,
while antibody titres against PAc are increased in patients with S. mutans IE, PAc did not play
a role in IE in a rat model of infection [69]. In contrast, a study examining the role of S.
mutans exopolysaccharides revealed a substantial decrease in the incidence of IE in rats infected
with wildtype S. mutans and a mutant lacking production of glucan and fructan polysacchar‐
ides [70]. Chia et al. later identified a direct interaction of S. mutans Xc rhamnose-glucose
polymers (RGPs) with both human and rabbit platelets and showed the resulting platelet
aggregation response to be mediated in part by anti-RGP IgGs [71]. Such rhamnose rich
polymers are common amongst streptococcci and may represent a conserved mechanism of
platelet activation by the Streptococcus genus [71].
8. High molecular weight repeat protein
Previous studies revealed that S. gordonii DL1 could bind to not only to platelet GPIbα but also
GPIIb, the α chain of the fibrinogen binding integrin αIIbβ3 [72]. Further studies identified a
large 397 kDa cell wall associated protein designated platelet adherence protein A (PadA) on
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the surface of S. gordonii which interacts with GPIIb [73]. The N-terminal fragment of PadA
contains a domain with homology to the A1 domain, the platelet interactive domain, of vWF.
This, however, showed no particular affinity for the vWF receptor, GPIbα. An isogenic PadA
mutant displayed the same affinity for glycocalicin as wildtype DL1 while binding was
significantly reduced in a Hsa mutant [73]. In contrast, platelets adhered to immobilised
fragments of the N-terminal region (amino acids 34-690) but not to a smaller fragment (amino
acids 34-359) also containing the vWF domain suggesting other sites within the protein
contribute to platelet adhesion to PadA [73]. Mutants lacking Hsa bound at wildtype levels to
Chinese Hamster Ovary (CHO) cells expressing αIIbβ3 while a PadA mutant displayed
significantly reduced adhesion. Additionally, CHO cell adhesion to wildtype bacteria was
inhibited by a monoclonal antibody to αIIbβ3 (abciximab) and a fibrinopeptide mimetic, RGDS
[73]. Interestingly, platelets adhering to immobilised S. gordonii DL1 or specific fragments of
PadA underwent dramatic changes in morphology as observed by fluorescent confocal
microscopy [74]. Rearrangement of the platelet actin cytoskeleton led filopodia and llameli‐
podia formation, known as platelet spreading [74]. Platelet spreading is critical for the platelet
to withstand shear forces experienced in the vasculature. Similar observations were made for
platelet adhesion to fibrinogen, suggesting that PadA mimics the prothrombotic surface of
immobilised extracellular matrix proteins. Indeed, protein analysis revealed PadA contains
RGD-like regions (RGG, RGT and AGD) that may act as binding sites for αIIbβ3 [74]. These
observations have led to the model of S. gordonii platelet interactions: Hsa and GspB mediate
initial attachment of S. gordonii to platelets via GPIbα; PadA provides stabilising interactions
via αIIbβ3, causing platelet spreading, so that the growing septic thrombus can resist the
turbulent forces within the bloodstream; and SspA and SspB are needed to produce the final
aggregation phase that propagates vegetation growth [59].
9. Phage encoded proteins
Human and bacterial evolution is peppered with incidences of viral integration or endogeni‐
sation into host genomes. Indeed, when the human genome was sequenced it was found that
only 1.5% was composed of defined genes [75, 76]. The remainder, formally referred to as “junk
DNA”, is now known to contain critical regulatory sequences. Many of these regulatory
sequences and indeed genes have been linked to viral origins [77-79]. Bacterial history is also
littered with incidences of viral DNA integration. Bacterial viruses are called bacteriophages
and in the cases below they confer an advantage to S. mitis in the pathogenesis of IE.
Using a transposon generated mutant library of S. mitis SF100, two genetic loci were identified
as having a role in S. mitis-platelet interactions [80]. The first, PblT, is predicted to encode a
transmembrane transporter with 12 membrane spanning segments [80]. Its role in S. mitis-
platelet interactions remains to be to be confirmed. Interestingly, the second locus was
demonstrated to be a bacteriophage, SM1, of the Siphoviridae family of bacteriophages [81] and
is widespread in the microbial population of the oropharynx and saliva as shown in a recent
metagenomic study of oral viral communities [82]. Two proteins, PblA and PblB, encoded in
the polycistronic operon of this phage were shown to mediate S. mitis binding to platelets [80,
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83]. PblA and PblB are expressed on the bacterial surface through a novel mechanism whereby
the proteins are exported and become associated with bacterial cells via choline residues in
their cell wall [84]. While the ability to bind choline residues is found in other streptococcal
expressed proteins (S. pneumoniae LytA), PblA and PblB bear little homology to previously
identified bacterial adhesins [80]. Instead, they are similar to the tail fibre proteins of phage
particles [80]. Recently a comprehensive study by Mitchell et al., utilizing linkage specific
sialidases, concluded that PblA and PblB bind sialic acid residues on α2-8 linked gangliosides
[85]. Consistent with this, platelets express only one such ganglioside, GD3, and specific
antibodies to this receptor significantly reduced binding of wild type S. mitis SF100 to platelets
while a mutant, with already significantly reduced in binding to platelets, remained unaffected
[85]. The precise role of this receptor in conventional platelet activation remains to be deter‐
mined but it has been shown to be upregulated on activated platelets, later becoming intern‐
alised and associating with the Src tyrosine kinase, Lyn, and then with FcRγ and leading to
increased FcγRIIA expression [86]. How S. mitis would propagate platelet activation through
this receptor remains to be elucidated.
Interestingly, during the investigation of PblA and PblB, a study revealed that mutation of the
bacteriophage lysin gene, lys, needed to permeablise cells and release lytic phage particles,
caused a reduction in platelet binding greater than that of the PblA-/PblB- mutant [84]. When
investigated further, the phage lysin was found to bind fibrinogen via the D fragment of the
Aα and Bβ chains, and in doing so can mediate an indirect interaction with human platelets
through αIIbβ3 [87]. Like PblA and PblB, it is also a choline binding protein but with homology
to the choline binding domain of pneumococcal LytA [87]. The fibrinogen interactive domain
was localized to amino acids 102-198 [88] and when this polypeptide was preincubated with
platelets and S. mitis SF100, it significantly extended the lag time to aggregation. Furthermore,
in a rat model of endocarditis, co-infection with PblA-/PblB- and lys- mutants led to substan‐
tially less inclusion of lys- S. mitis in the vegetations as compared to the tail protein mutant,
PblA-/PblB-. LysinSM1 is considered a multifunctional phage protein, mediating lysis of S.
mitis in the bacteriophage lytic life cycle, binding to choline residues in the cell wall and binding
to fibrinogen, bridging an interaction with human platelets via αIIbβ3 [87], an interaction that
is repeated in multiple streptococcal species and considered an important interaction in the
pathogenesis of IE (see figure).
10. Secreted products
Bacteria can secrete bioactive molecules that participate in platelet interactions in trans,
independently of bacterial cell binding. Early studies examining the role of aetiological agents
in Kawasaki disease (an inflammatory disease characterised by systemic vasculitis) isolated a
strain of S mitis (Nm65) whose culture supernatant appeared to induce platelet aggregation in
platelet rich plasma [89]. This activity was isolated to a heat labile, 66kDa protein antigen called
sm-hPAF (S. mitis derived human platelet aggregation factor) [90]. Notably, ‘aggregation’ was
not inhibited by treatment of platelets with prostaglandin E1 (PGE1), which increases intracel‐
lular cyclic-AMP preventing platelet signalling, or the αIIbβ3 inhibitory peptide (RGDS) and
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was considered to induce platelet aggregation via novel mechanism [90]. With developments
in our understanding of platelet aggregation, inhibition of platelet signalling and activation
by PGE1 and αIIbβ3 dependency are hallmarks of true platelet aggregation. Sm-hPAF (Nm-65
derived) and lectinolysin (SK597derived) were later purified independently and identified as
members of the cholesterol dependent cytolysin (CDC) family of bacterial toxins which form
oligomeric lytic pores in erythrocyte membranes [90, 91]. Both lectinolysin and Sm-hPAF
possess an additional N-terminal fucose binding domain homologous to an agglutinin from
the eel species Anguilla Anguilla. Interstingly, lectinolysin was demonstrated to induce pore
formation via a mechanism modulated by fucosylated glycan binding to the N-terminal
domain [91]. However, this domain did not participate in initial receptor recognition as lysis
was detected in the absence of a functional glycan binding domain [91] and additional
members of the CDC family lacking this domain, suislysin and pneumolysin, also induced
platelet lysis [92]. The role of platelet lysis in IE remains to be established.
11. Streptococcal-platelet interactions — Signalling response
Following platelet activation platelets secrete signalling molecules and platelet agonists from
their cytoplasmic granules to recruit and activate nearby platelets. S. sanguinis can modulate
the platelet response through an unusual interaction whereby a surface associated enzyme can
modify secreted platelet agonists. Early studies by Herzberg et al. demonstrated that S.
sanguinis could hydrolyse exogenous ATP to ADP and this was postulated as a mechanism
causing platelet aggregation as a cell free supernatant of S. sanguinis preincubated with ATP
could induce platelet aggregation almost immediately [93]. Later MacFarlane et al. demon‐
strated that this ecto-ATPase activity localized to a cell wall fraction of S. sanguinis [94]. Fan et
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Figure 1. Schematic of streptococcal platelet interactions in infective endocarditis.
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 which can hydrolyse ATP, ADP and AMP producing adenosine [95]. A mutant lacking Nt5e
expression had a shortened lag time to platelet aggregation with no effect on platelet adhesion
but, interestingly, had decreased virulence in a rabbit model of IE as compared to the wildtype.
This was suggested to be due to the inhibition of professional phagocytes, monocytes and
macrophages by adenosine, an anti-inflammatory molecule [95]. In addition, the delay in
platelet aggregation may delay the release of platelet microbicidal proteins from their granules
thus inhibiting the platelet immune response [95].
As mentioned, platelets spread on S. gordonii DL1. While platelet spreading is critical for
thrombus stability, dense granule secretion is important for amplification of the platelet
response, facilitating activation of nearby platelets, recruiting them to the growing thrombus.
Both result from initiation of an intracellular signalling cascade caused by PadA engagement
of αIIbβ3 [74]. Interestingly, inhibition of platelet FcγRIIA by a monoclonal antibody (Clone
IV.3) prevented both platelet spreading and dense granule secretion [74]. FcγRIIA is an ITAM
containing receptor [96]. It has an extracellular domain that interacts with immune complexes
and an intracellular domain which is proposed to act as a signalling scaffold allowing recruit‐
ment protein kinases and phosphatases. Following platelet adhesion and spreading on S.
gordonii DL1, immunopercipitation of FcγRIIA and its downstream effectors revealed tyrosine
phosphorylation of FcγRIIA, Syk and phospholipase Cγ (PLCγ – an effector of dense granule
secretion) [74]. Blockade of FcγRIIA by the antibody IV.3 prevented phosphorylation of
FcγRIIA and its downstream effectors while it had no effect on platelet adhesion to S. gordo‐
nii DL1 demonstrating an essential role in platelet activation and signalling but not in initial
attachment to the bacterium.
Similarly, Pampolina et al. examined the phosphorylation state of the FcγRIIA and its down‐
stream effectors during the platelet aggregation response to S. sanguinis 2017-78. S. sanguinis
2017-78 induced phosphorylation of FcγRIIA, Syk, Linker for activation of T-cells (LAT) and
PLCγ 30 seconds after the addition of bacteria to the platelet suspension [97]. This was followed
by dephosphorylation during the lag phase and αIIbβ3 and thromboxane dependent rephos‐
phorylation as aggregation proceeded [97]. The MAP kinase Erk was observed to follow the
same triphasic phosphorylation profile in response to S. sanguinis 2017-78 [98]. The dephos‐
phorylation phase is proposed to be due to the activity of platelet endothelial cell adhesion
molecule-1 (PECAM-1), an ITIM containing receptor which recruits the tyrosine phosphatase
SHP-1 during the lag phase [97]. Further studies by McNicol et al. highlighted a role for PI3
kinase mediated phosphorylation of Erk in response to S. sanguinis 2017-78 [99]. PI3 kinase is
found downstream of FcγRIIA and GPIb and upstream of the GTPase Rap1b, critical for
αIIbβ3 activation [100, 101].
12. Streptococcal-platelet interactions — Immunological response
When bacteria enter the bloodstream they are recognised by soluble elements of the immune
system. These soluble elements, specifically immunoglobulins and complement proteins can
bind to their respective receptors on professional immune cells and platelets forming indirect
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bridging interactions. As most bacteria causing infective endocarditis are in fact lifelong or
transient residents of the host, most of the population inherently produce a humoral immune
response to these bacteria.
The  role  of  IgG  in  platelet  bacterial  interactions  has  been  extensively  studied  and
reaffirmed  repeatedly  in  the  literature  [28,  102-105].  Its  role  was  first  confirmed  by
Sullam  et  al.  who  demonstrated  that  plasma  components  other  than  fibrinogen  (a
cofactor  for  ADP  induced  activation)  was  required  for  S.  sanguinis  M99  and  S.  salivar‐
ius  D1  induced  platelet  aggregation  [104].  Additionally,  blockade  of  the  platelet  low
affinity  IgG  receptor,  FcγRIIA,  with  a  monoclonal  antibody  IV.3  completely  inhibited
platelet  aggregation in response to these bacteria  [104].  In fact,  inhibition of  FcγRIIA has
inhibited all  bacterial  induced aggregation  when examined,  even in  the  absence  of  IgG
interactions  consolidating  its  role  in  platelet  activation  by  bacteria  [30,  74,  84,  97,  102,
106-108].  The  nature  of  these  antibodies,  however,  remains  more  complex  as  some
bacteria  require  strain  specific  [107],  species  specific  or,  minimally,  group  specific
antibodies  [105].  Many  conserved  structural  entities  of  bacteria  elicit  antibody  respons‐
es  e.g.,  peptidoglycan  and  lipoteichoic  acids.  Therefore,  it  is  plausible  that  specific
subclasses  of  antibody  cross  react  between  streptococcal  species  while  others  recognise
species  and  strain  specific  antigens.  Indeed,  while  IgG1  and  IgG3  largely  bind  protein
antigens,  IgG2  binds  to  carbohydrate  antigens  [109].  Antibody  levels  in  the  host  were
first  thought to determine the variable  lag times observed between donors however this
could  not  be  established  and  led  to  investigations  of  other  plasma  proteins  mediating
platelet-bacterial  interactions.  Additionally,  in  a  study of  aggregating and non aggregat‐
ing  strains  of  S.  sanguinis  and  S.  gordonii,  significant  correlation  between  the  levels  of
specific  antibody and the  propensity  to  induce  aggregation was  observed,  but  this  was
not  true  for  all  donors  [105].  Notably,  non  aggregating  strains  and their  non  aggregat‐
ing donor pairs  were shown to have similar  levels  of  strain specific  antibody to donors
who did  support  platelet  aggregation  [105].  This  was  not  explained by  polymorphisms
in FcγRIIA and thus is  most  likely a result  of  secondary interactions with other receptors,
differences  in  receptor  number  or  polymorphisms  therein  but  this  remains  to  be
investigated.
The complement system is  a  series of  proteins that  bind to bacteria in a step wise fashion
and  culminate  in  the  formation  of  an  oligomeric  pore,  the  membrane  attack  complex,
which  lyses  the  targeted  bacterium.  Roles  for  complement  in  bacterial-platelet  interac‐
tions  have  been  demonstrated  in  Staphylococcal  aureus  and  S.  sanguinis  [102,  107,  110].
The  lag  time  to  aggregation  in  platelet  rich  plasma  (PRP)  in  response  to  S.  sanguinis
7863  is  7-19  minutes  [111]  and this  variation  was  correlated  to  the  rate  of  assembly  of
the  C5b-9  complex  on  the  surface  of  the  bacteria  as  detected  by  flow  cytometry  [110].
Accordingly,  the lag time to  aggregation using bacterial  cells  preincubated with plasma
before  addition  to  PRP could  be  progressively  shortened with  extension  of  the  incuba‐
tion time [110].  Complement  activation can be triggered by antigen-antibody complexes
(classical  pathway)  or  by binding of  specific  complement  proteins  (alternative pathway)
or  mannose  binding protein  (lectin  pathway)  to  the  microbial  surface.  S.  sanguinis  7863
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induced  the  alternative  pathway,  as  shown  by  direct  and  Mg2+  dependent  binding  of
complement  protein  C3  to  the  surface  of  the  bacterium  [110].  Inactivation  of  comple‐
ment by cobra venom or heat  treatment abolished aggregation [110]  suggesting that  other
interactions,  namely IgG with FcγRIIA,  were not  sufficient  to produce aggregation alone.
It  is  not  known  precisely  how  complement  activation  triggers  platelet  activation  but  it
is  possible  that  there  is  a  threshold  of  bacterial-platelet  interactions  (capable  of  induc‐
ing strong or weak signals)  which much be surpassed before triggering platelet  aggrega‐
tion however this  remains to be investigated.
While previous reports examined platelet secretion in terms of end stage platelet activation,
namely aggregation and spreading, a number of studies exist investigating the role of platelet
secretion in the context of platelet immunology. In addition to platelet agonists, platelet
granules contain bacteriocidal proteins and cytokines. A recent study by McNicol et al.
demonstrated platelet activity in the form of signalling and secretion in the absence of platelet
aggregation. They examined platelet secretion of soluble inflammatory mediators (Platelet
factor 4, RANTES, sCD40L, platelet derived growth factor) in response to a number of S.
sanguinis and S. gordonii strains and paired these with their platelet aggregation responses. All
strains triggered secretion of cytokines irrespective of the platelet aggregation response but
only 1 strain (S. sanguinis 2017-78) triggered release of sCD62p [99]. For S. sanguinis 2017-78
cytokine secretion was independent of thromboxane production and aggregation. Interest‐
ingly this secretion response was inhibited by low doses of epinephrine while aggregation and
protein phosphorylation cascades mentioned previously were enhanced [99]. The inhibition
of platelet activation by epinephrine has not been noted in response to any other platelet
agonists and adds another layer of complexity to bacterial induced platelet activation. It will
be interesting to examine the contribution of individual platelet-bacterial interactions this
novel platelet activation in the future.
13. Conclusion
The overall role of platelet activation in response to circulating bacteria and IE is controversial
but recent studies have linked platelet activation to the ability of bacteria to resist antibiotics
[112]. This is consistent with the concept that, in activating platelets, bacteria prevent infiltra‐
tion by antibiotics (or recognition by the immune system). It is likely that the initial adhesion
events occur independently of platelet activation and thus make suitable targets in the
prevention of IE. In contrast, as the ability to induce platelet aggregation (activation) in vitro
contributes to the virulence and persistence of the organism in infective endocarditis animal
models [87, 95], the pathways of platelet aggregation are targets of future IE therapies.
Consistent with this, a recent study has examined the effect of antiplatelet drug Reopro
(abciximab) in the treatment of sepsis in mice [113] and the use of cyclooxygenase inhibitors,
e.g. aspirin and inbuprofen continue to be investigated [114-117]. Critically, future therapies
must balance immune function and haemostatic function of platelets making thorough
understanding of platelet-bacterial interactions and bacterial induced platelet activation
essential for future drug development.
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